4-(5-异喹啉)-1-哌嗪羧酸 1,1-二甲基乙酯 | 444620-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(5-异喹啉)-1-哌嗪羧酸 1,1-二甲基乙酯
• 中文别名: 4-(5-异喹啉)-1-哌嗪羧酸1,1-二甲基乙酯
• 英文名称: 4-isoquinoline-5-yl-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-(isoquinolin-5-yl)piperazine-1-carboxylate；tert-butyl 4-isoquinolin-5-ylpiperazine-1-carboxylate
• CAS: 444620-69-3
• 化学式: C₁₈H₂₃N₃O₂
• 分子量: 313.4
• InChiKey: NHFVAONVLCETEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(5-异喹啉)-1-哌嗪羧酸 1,1-二甲基乙酯 在 铂 氢气 、 三氟乙酸 作用下， 生成 2-Methanesulfonyl-5-piperazin-1-yl-1,2,3,4-tetrahydro-isoquinoline
  参考文献：
  名称：

  Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines

  摘要：

  Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.035
• 作为产物：
  描述：

  5-溴异喹啉 在 sodium acetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 生成 4-(5-异喹啉)-1-哌嗪羧酸 1,1-二甲基乙酯
  参考文献：
  名称：

  Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines

  摘要：

  Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.035

文献信息

• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
  申请人：AMGEN INC

  公开号：WO2004035549A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

  式（I）的化合物在治疗辣椒素受体介导的疾病方面很有用，如炎症性或神经病痛以及涉及感觉神经功能的疾病，如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。
• Substituted tetrahydroisoquinolines and uses thereof
  申请人：Roche Palo Alto LLC

  公开号：US20040180874A1

  公开（公告）日：2004-09-16

  The invention provides compounds of the formula: 1 and pharmaceutically acceptable salts or prodrugs thereof, wherein, n, X, Y, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

  这项发明提供了以下式的化合物： 1 及其药学上可接受的盐或前药，其中，n、X、Y、R 1 、R 2 、R 3 、R 4 和R 5 如本文所定义。该发明还提供了制备方法、包含化合物I的组合物以及使用化合物I的方法。
• [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS<br/>[FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLÉINE SUBSTITUÉS COMME INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013056060A1

  公开（公告）日：2013-04-18

  The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

  本发明提供了式（I）的化合物：或其立体异构体，以及这些化合物的药用可接受的盐，其中所有变量均如本文所定义。这些化合物是XIa因子和/或血浆激肽原酶的抑制剂，可用作药物。
• Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
  作者：Donald J. P. Pinto、Michael J. Orwat、Leon M. Smith、Mimi L. Quan、Patrick Y. S. Lam、Karen A. Rossi、Atsu Apedo、Jeffrey M. Bozarth、Yiming Wu、Joanna J. Zheng、Baomin Xin、Nathalie Toussaint、Paul Stetsko、Olafur Gudmundsson、Brad Maxwell、Earl J. Crain、Pancras C. Wong、Zhen Lou、Timothy W. Harper、Silvi A. Chacko、Joseph E. Myers、Steven Sheriff、Huiping Zhang、Xiaoping Hou、Arvind Mathur、Dietmar A. Seiffert、Ruth R. Wexler、Joseph M. Luettgen、William R. Ewing

  DOI：10.1021/acs.jmedchem.7b01171

  日期：2017.12.14

  Factor XIa (FXIa) is a blood coagulation enzyme that is involved in the amplification of thrombin generation. Mounting evidence suggests that direct inhibition of FXIa can block pathologic thrombus formation while preserving normal hemostasis. Preclinical studies using a variety of approaches to reduce FXIa activity, including direct inhibitors of FXIa, have demonstrated good antithrombotic efficacy

  XIa因子（FXIa）是一种凝血酶，参与凝血酶生成的扩增。越来越多的证据表明，直接抑制FXIa可以阻止病理性血栓形成，同时保持正常止血。临床前研究使用多种降低FXIa活性的方法，包括FXIa的直接抑制剂，已证明在不增加出血的情况下具有良好的抗血栓形成作用。在此潜力的基础上，我们着力于确定FXIa的有效抑制剂，重点是发现一种可在医院环境中使用的急性抗血栓形成剂。本文中，我们描述了一种有效的FXIa临床候选物55（FXIa K i= 0.7 nM），在血栓形成模型中具有出色的临床前功效，并且水溶性适合静脉内给药。BMS-962212是FXIa的可逆，直接和高选择性小分子抑制剂。
• Vanilloid receptor ligands and their use in treatments
  申请人：Amgen Inc.

  公开号：US20040152690A1

  公开（公告）日：2004-08-05

  Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, bums, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  治疗苯并咪唑和含有苯并咪唑的组合物，用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合症、紧张性头痛、一般炎症、关节炎、风湿病、骨关节炎、炎症性肠病、炎症性眼疾、炎症性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤疾病、慢性炎症病状、炎症性疼痛及相关的高敏感性和痛觉过敏、神经痛及相关的高敏感性和痛觉过敏、糖尿病神经病疼痛、烧伤后疼痛、交感神经维持性疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、胃肠或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃病变、头发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。